Literature DB >> 33382642

Predictors of mortality in invasive pneumococcal disease: a meta-analysis.

Tuna Demirdal1, Pinar Sen1, Busra Emir2.   

Abstract

OBJECTIVES: To assess risk factors for mortality in invasive pneumococcal disease (IPD).
METHODS: We conducted a systemic literature search in January 2019. The main outcome measure included death within 30 days after diagnosis of IPD. The study protocol was registered in PROSPERO (CRD42019120189).
RESULTS: After reviewing 2514 potentially relevant records, remaining 190 articles were included in the analysis. A total of 228,782 IPD patients were identified and the mortality rate was 17.2% in the included articles. No significant evidence of publication bias was found according to the funnel plot and Egger's test (t = 1.464, p = 0.145). Male sex, older age, alcohol abuse, previous tuberculosis, meningitis, hospital acquired infections, multilobar infiltrate or effusion, Pitt bacteremia score≥4, Pneumonia Severity Index≥4, clinical conditions requiring intensive care, underlying clinical conditions, disease caused by serotypes 3, 6B, 9 N, 10A, 11A, 16 F, 17 F, 19, 19 F, 22 F, 23A, 23 F, 31 and 35 F, previous antibiotic use, inappropriate initial antibiotic therapy, penicillin resistance, and vancomycin use during the course of treatment were predicators of 30-day mortality.
CONCLUSIONS: This meta-analysis highlights important risk factors for IPD-related mortality, many of which may be targeted through preventive measures.

Entities:  

Keywords:  Invasive pneumococcal disease; meta-analysis; mortality; pneumococcal infection; risk factors; streptococcus pneumoniae

Year:  2020        PMID: 33382642     DOI: 10.1080/14787210.2021.1858799

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  3 in total

Review 1.  Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.

Authors:  Chiara Scelfo; Francesco Menzella; Matteo Fontana; Giulia Ghidoni; Carla Galeone; Nicola Cosimo Facciolongo
Journal:  Vaccines (Basel)       Date:  2021-04-22

2.  Antimicrobial Susceptibility Pattern and Serotype Distribution of Streptococcus pneumoniae Isolates From a Hospital-Based Study in Chandigarh, North India.

Authors:  Swati Sharma; Monica Sharma; Pallab Ray; Anuradha Chakraborti
Journal:  Cureus       Date:  2022-01-19

3.  Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).

Authors:  Laura L Hammitt; Dean Quinn; Ewa Janczewska; Francisco J Pasquel; Richard Tytus; K Rajender Reddy; Katia Abarca; Ilsiyar M Khaertynova; Ron Dagan; Jennifer McCauley; Kyeongmi Cheon; Alison Pedley; Tina Sterling; Gretchen Tamms; Luwy Musey; Ulrike K Buchwald
Journal:  Open Forum Infect Dis       Date:  2021-12-18       Impact factor: 3.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.